Near infrared fluorescent nanoparticles derived from hyaluronic acid improve tumor contrast for image-guided surgery

Tanner K. Hill, Sneha S. Kelkar, Nicholas E. Wojtynek, Joshua J. Souchek, William M. Payne, Kristina Stumpf, Frank C. Marini, Aaron M Mohs

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Tumor tissue that remains undetected at the primary surgical site can cause tumor recurrence, repeat surgery, and treatment strategy alterations that impose a significant patient and healthcare burden. Intraoperative near infrared fluorescence (NIRF) imaging is one potential method to identify remaining tumor by visualization of NIR fluorophores that are preferentially localized to the tumor. This requires development of fluorophores that consistently identify tumor tissue in different patients and tumor types. In this study we examined a panel of NIRF contrast agents consisting of polymeric nanoparticle (NP) formulations derived from hyaluronic acid (HA), with either physically entrapped indocyanine green (ICG) or covalently conjugated Cy7.5. Using orthotopic human breast cancer MDA-MB-231 xenografts in nude mice we identified two lead formulations. One, NanoICGPBA, with physicochemically entrapped ICG, showed 2.3-fold greater tumor contrast than ICG alone at 24 h (p < 0.01), and another, NanoCy7.5100-H, with covalently conjugated Cy7.5, showed 74-fold greater tumor contrast than Cy7.5 alone at 24 h (p < 0.0001). These two lead formulations were then tested in immune competent BALB/c mice bearing orthotopic 4T1 breast cancer tumors. NanoICGPBA showed 2.2-fold greater contrast than ICG alone (p < 0.0001), and NanoCy7.5100-H showed 14.8-fold greater contrast than Cy7.5 alone (p < 0.0001). Furthermore, both NanoICGPBA and NanoCy7.5100-H provided strong tumor enhancement using image-guided surgery in mice bearing 4T1 tumors. These studies demonstrate the efficacy of a panel of HA-derived NPs in delineating tumors in vivo, and identifies promising formulations that can be used for future in vivo tumor removal efficacy studies.

Original languageEnglish (US)
Pages (from-to)2314-2328
Number of pages15
JournalTheranostics
Volume6
Issue number13
DOIs
StatePublished - Jan 1 2016

Fingerprint

Computer-Assisted Surgery
Hyaluronic Acid
Nanoparticles
Neoplasms
Indocyanine Green
Breast Neoplasms
Optical Imaging
Fluorescent Dyes
Reoperation
Heterografts
Nude Mice
Contrast Media

Keywords

  • Near infrared fluorescence

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Near infrared fluorescent nanoparticles derived from hyaluronic acid improve tumor contrast for image-guided surgery. / Hill, Tanner K.; Kelkar, Sneha S.; Wojtynek, Nicholas E.; Souchek, Joshua J.; Payne, William M.; Stumpf, Kristina; Marini, Frank C.; Mohs, Aaron M.

In: Theranostics, Vol. 6, No. 13, 01.01.2016, p. 2314-2328.

Research output: Contribution to journalArticle

Hill, TK, Kelkar, SS, Wojtynek, NE, Souchek, JJ, Payne, WM, Stumpf, K, Marini, FC & Mohs, AM 2016, 'Near infrared fluorescent nanoparticles derived from hyaluronic acid improve tumor contrast for image-guided surgery', Theranostics, vol. 6, no. 13, pp. 2314-2328. https://doi.org/10.7150/thno.16514
Hill, Tanner K. ; Kelkar, Sneha S. ; Wojtynek, Nicholas E. ; Souchek, Joshua J. ; Payne, William M. ; Stumpf, Kristina ; Marini, Frank C. ; Mohs, Aaron M. / Near infrared fluorescent nanoparticles derived from hyaluronic acid improve tumor contrast for image-guided surgery. In: Theranostics. 2016 ; Vol. 6, No. 13. pp. 2314-2328.
@article{cce294cd80b647bdadf6b26eb837327f,
title = "Near infrared fluorescent nanoparticles derived from hyaluronic acid improve tumor contrast for image-guided surgery",
abstract = "Tumor tissue that remains undetected at the primary surgical site can cause tumor recurrence, repeat surgery, and treatment strategy alterations that impose a significant patient and healthcare burden. Intraoperative near infrared fluorescence (NIRF) imaging is one potential method to identify remaining tumor by visualization of NIR fluorophores that are preferentially localized to the tumor. This requires development of fluorophores that consistently identify tumor tissue in different patients and tumor types. In this study we examined a panel of NIRF contrast agents consisting of polymeric nanoparticle (NP) formulations derived from hyaluronic acid (HA), with either physically entrapped indocyanine green (ICG) or covalently conjugated Cy7.5. Using orthotopic human breast cancer MDA-MB-231 xenografts in nude mice we identified two lead formulations. One, NanoICGPBA, with physicochemically entrapped ICG, showed 2.3-fold greater tumor contrast than ICG alone at 24 h (p < 0.01), and another, NanoCy7.5100-H, with covalently conjugated Cy7.5, showed 74-fold greater tumor contrast than Cy7.5 alone at 24 h (p < 0.0001). These two lead formulations were then tested in immune competent BALB/c mice bearing orthotopic 4T1 breast cancer tumors. NanoICGPBA showed 2.2-fold greater contrast than ICG alone (p < 0.0001), and NanoCy7.5100-H showed 14.8-fold greater contrast than Cy7.5 alone (p < 0.0001). Furthermore, both NanoICGPBA and NanoCy7.5100-H provided strong tumor enhancement using image-guided surgery in mice bearing 4T1 tumors. These studies demonstrate the efficacy of a panel of HA-derived NPs in delineating tumors in vivo, and identifies promising formulations that can be used for future in vivo tumor removal efficacy studies.",
keywords = "Near infrared fluorescence",
author = "Hill, {Tanner K.} and Kelkar, {Sneha S.} and Wojtynek, {Nicholas E.} and Souchek, {Joshua J.} and Payne, {William M.} and Kristina Stumpf and Marini, {Frank C.} and Mohs, {Aaron M}",
year = "2016",
month = "1",
day = "1",
doi = "10.7150/thno.16514",
language = "English (US)",
volume = "6",
pages = "2314--2328",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "13",

}

TY - JOUR

T1 - Near infrared fluorescent nanoparticles derived from hyaluronic acid improve tumor contrast for image-guided surgery

AU - Hill, Tanner K.

AU - Kelkar, Sneha S.

AU - Wojtynek, Nicholas E.

AU - Souchek, Joshua J.

AU - Payne, William M.

AU - Stumpf, Kristina

AU - Marini, Frank C.

AU - Mohs, Aaron M

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Tumor tissue that remains undetected at the primary surgical site can cause tumor recurrence, repeat surgery, and treatment strategy alterations that impose a significant patient and healthcare burden. Intraoperative near infrared fluorescence (NIRF) imaging is one potential method to identify remaining tumor by visualization of NIR fluorophores that are preferentially localized to the tumor. This requires development of fluorophores that consistently identify tumor tissue in different patients and tumor types. In this study we examined a panel of NIRF contrast agents consisting of polymeric nanoparticle (NP) formulations derived from hyaluronic acid (HA), with either physically entrapped indocyanine green (ICG) or covalently conjugated Cy7.5. Using orthotopic human breast cancer MDA-MB-231 xenografts in nude mice we identified two lead formulations. One, NanoICGPBA, with physicochemically entrapped ICG, showed 2.3-fold greater tumor contrast than ICG alone at 24 h (p < 0.01), and another, NanoCy7.5100-H, with covalently conjugated Cy7.5, showed 74-fold greater tumor contrast than Cy7.5 alone at 24 h (p < 0.0001). These two lead formulations were then tested in immune competent BALB/c mice bearing orthotopic 4T1 breast cancer tumors. NanoICGPBA showed 2.2-fold greater contrast than ICG alone (p < 0.0001), and NanoCy7.5100-H showed 14.8-fold greater contrast than Cy7.5 alone (p < 0.0001). Furthermore, both NanoICGPBA and NanoCy7.5100-H provided strong tumor enhancement using image-guided surgery in mice bearing 4T1 tumors. These studies demonstrate the efficacy of a panel of HA-derived NPs in delineating tumors in vivo, and identifies promising formulations that can be used for future in vivo tumor removal efficacy studies.

AB - Tumor tissue that remains undetected at the primary surgical site can cause tumor recurrence, repeat surgery, and treatment strategy alterations that impose a significant patient and healthcare burden. Intraoperative near infrared fluorescence (NIRF) imaging is one potential method to identify remaining tumor by visualization of NIR fluorophores that are preferentially localized to the tumor. This requires development of fluorophores that consistently identify tumor tissue in different patients and tumor types. In this study we examined a panel of NIRF contrast agents consisting of polymeric nanoparticle (NP) formulations derived from hyaluronic acid (HA), with either physically entrapped indocyanine green (ICG) or covalently conjugated Cy7.5. Using orthotopic human breast cancer MDA-MB-231 xenografts in nude mice we identified two lead formulations. One, NanoICGPBA, with physicochemically entrapped ICG, showed 2.3-fold greater tumor contrast than ICG alone at 24 h (p < 0.01), and another, NanoCy7.5100-H, with covalently conjugated Cy7.5, showed 74-fold greater tumor contrast than Cy7.5 alone at 24 h (p < 0.0001). These two lead formulations were then tested in immune competent BALB/c mice bearing orthotopic 4T1 breast cancer tumors. NanoICGPBA showed 2.2-fold greater contrast than ICG alone (p < 0.0001), and NanoCy7.5100-H showed 14.8-fold greater contrast than Cy7.5 alone (p < 0.0001). Furthermore, both NanoICGPBA and NanoCy7.5100-H provided strong tumor enhancement using image-guided surgery in mice bearing 4T1 tumors. These studies demonstrate the efficacy of a panel of HA-derived NPs in delineating tumors in vivo, and identifies promising formulations that can be used for future in vivo tumor removal efficacy studies.

KW - Near infrared fluorescence

UR - http://www.scopus.com/inward/record.url?scp=84999622563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999622563&partnerID=8YFLogxK

U2 - 10.7150/thno.16514

DO - 10.7150/thno.16514

M3 - Article

C2 - 27877237

AN - SCOPUS:84999622563

VL - 6

SP - 2314

EP - 2328

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 13

ER -